News
Innovent Presents Updated Data From Innovative Anti-CLDN18.2 ADC (IBI343) Phase 1 Study in Patients with Advanced Pancreatic Cancer at the ESMO Asia Congress 2024
SAN FRANCISCO and SUZHOU, China, Dec. 9, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of onco
By: prnewswire_apac
- Dec 09 2024
- 0
- 0 Views
ONLY AVAILABLE IN PAID PLANS